{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:57:10Z","timestamp":1753358230491},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T00:00:00Z","timestamp":1361404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s13577-013-0062-y","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T11:35:15Z","timestamp":1361360115000},"page":"121-127","source":"Crossref","is-referenced-by-count":13,"title":["Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene"],"prefix":"10.1007","volume":"26","author":[{"given":"Hiroaki","family":"Itamochi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Oumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Naniwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kudoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Terakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Kigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasuku","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,21]]},"reference":[{"key":"62_CR1","first-page":"5","volume":"42","author":"RE Scully","year":"1975","unstructured":"Scully RE. World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr. 1975;42:5\u20137.","journal-title":"Natl Cancer Inst Monogr"},{"issue":"4","key":"62_CR2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1349-7006.2008.00747.x","volume":"99","author":"H Itamochi","year":"2008","unstructured":"Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99(4):653\u20138.","journal-title":"Cancer Sci"},{"issue":"6","key":"62_CR3","first-page":"860","volume":"37","author":"JC Aure","year":"1971","unstructured":"Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary. Clinical and histopathologic studies. Obstet Gynecol. 1971;37(6):860\u20137.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"62_CR4","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88(11):2584\u20139.","journal-title":"Cancer"},{"issue":"10","key":"62_CR5","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/sj.bjc.6603116","volume":"94","author":"M Takano","year":"2006","unstructured":"Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94(10):1369\u201374.","journal-title":"Br J Cancer"},{"issue":"Pt 3","key":"62_CR6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/0264-6021:3460561","volume":"346","author":"B Vanhaesebroeck","year":"2000","unstructured":"Vanhaesebroeck B, Alessi DR. The PI3K\u2013PDK1 connection: more than just a road to PKB. Biochem J. 2000;346(Pt 3):561\u201376.","journal-title":"Biochem J"},{"issue":"7","key":"62_CR7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489\u2013501.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"62_CR8","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-09-3004","volume":"16","author":"MS Heijden van der","year":"2010","unstructured":"van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res. 2010;16(12):3094\u20139.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"62_CR9","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","volume":"174","author":"KT Kuo","year":"2009","unstructured":"Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597\u2013601.","journal-title":"Am J Pathol"},{"issue":"2","key":"62_CR10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/path.2940","volume":"225","author":"S Yamamoto","year":"2011","unstructured":"Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol. 2011;225(2):189\u201394.","journal-title":"J Pathol"},{"key":"62_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-5-29","volume":"5","author":"VS Li","year":"2005","unstructured":"Li VS, Wong CW, Chan TL, et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005;5:29.","journal-title":"BMC Cancer"},{"issue":"6","key":"62_CR12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","volume":"7","author":"Y Samuels","year":"2005","unstructured":"Samuels Y, Diaz LA Jr, Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7(6):561\u201373.","journal-title":"Cancer Cell"},{"issue":"2","key":"62_CR13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0029-7844(02)02040-9","volume":"100","author":"H Itamochi","year":"2002","unstructured":"Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100(2):281\u20137.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"62_CR14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000065067","volume":"62","author":"H Itamochi","year":"2002","unstructured":"Itamochi H, Kigawa J, Akeshima R, et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology. 2002;62(4):349\u201353.","journal-title":"Oncology"},{"issue":"3","key":"62_CR15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ygyno.2011.05.003","volume":"122","author":"H Itamochi","year":"2011","unstructured":"Itamochi H, Yoshida T, Walker CL, et al. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol. 2011;122(3):641\u20137.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"62_CR16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.2910500502","volume":"50","author":"MT Dimanche-Boitrel","year":"1992","unstructured":"Dimanche-Boitrel MT, Pelletier H, Genne P, et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer. 1992;50(5):677\u201382.","journal-title":"Int J Cancer"},{"issue":"12","key":"62_CR17","first-page":"3551","volume":"50","author":"MH Barcellos-Hoff","year":"1990","unstructured":"Barcellos-Hoff MH, Marton LJ, Deen DF. Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells. Cancer Res. 1990;50(12):3551\u20135.","journal-title":"Cancer Res"},{"issue":"7","key":"62_CR18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502\u201316.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"62_CR19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4331\/wjbc.v1.i7.209","volume":"1","author":"H Itamochi","year":"2010","unstructured":"Itamochi H. Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem. 2010;1(7):209\u201320.","journal-title":"World J Biol Chem"},{"issue":"5670","key":"62_CR20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.","journal-title":"Science"},{"issue":"12","key":"62_CR21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nrc1753","volume":"5","author":"AG Bader","year":"2005","unstructured":"Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5(12):921\u20139.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"62_CR22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrd3527","volume":"10","author":"D Holmes","year":"2011","unstructured":"Holmes D. PI3K pathway inhibitors approach junction. Nat Rev Drug Discov. 2011;10(8):563\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"62_CR23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"62_CR24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/path.2848","volume":"223","author":"MK McConechy","year":"2011","unstructured":"McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 2011;223(5):567\u201373.","journal-title":"J Pathol"},{"issue":"4","key":"62_CR25","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ajpath.2011.01.009","volume":"178","author":"IeM Shih","year":"2011","unstructured":"Shih IeM, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol. 2011;178(4):1442\u20137.","journal-title":"Am J Pathol"},{"issue":"6","key":"62_CR26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075\u201383.","journal-title":"J Clin Oncol"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-013-0062-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13577-013-0062-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-013-0062-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T16:25:25Z","timestamp":1559492725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13577-013-0062-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,21]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s13577-013-0062-y","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,21]]}}}